{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'PROTOCOL SYNOPSIS', 'Protocol Title', 'ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With', 'Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX', 'Product Name', 'Fitusiran (INN); SAR439774 (formerly Alnylam ALN-AT3SC)', 'Indication', 'Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and adolescent', '(12 years old) hemophilia A or B patients', 'Phase', '3', 'Study Centers', 'The study will be conducted at approximately 100 clinical study centers worldwide.', 'Objectives', 'Primary', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with factor', 'concentrates, as determined by the frequency of bleeding episodes', 'Secondary', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with factor', 'concentrates, as determined by:', '- The frequency of spontaneous bleeding episodes', '- The frequency of joint bleeding episodes', '-', 'Health-related quality of life (HRQOL) in patients >17 years of age', 'To determine the frequency of bleeding episodes during the onset period', 'To determine the safety and tolerability of fitusiran', 'Exploratory', 'To evaluate the effects of fitusiran as compared to on-demand treatment with factor', 'concentrates on the following patient-reported outcomes:', '- Patient satisfaction with treatment', '-', 'Patient activity', '-', 'HRQOL in adolescents (12 to <17 years of age)', 'To characterize the pharmacodynamic (PD) effect, pharmacokinetics (PK), and', 'immunogenicity of fitusiran', 'To evaluate the effects of fitusiran as compared to on-demand treatment with factor', 'Property of the Sanofi Group - strictly confidential', '6', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'concentrates on the total weight-adjusted consumption of factor concentrates', 'To evaluate the effects of fitusiran as compared to on-demand treatment with factor', 'concentrates on joint status', 'To evaluate the effects of fitusiran as compared to on-demand treatment with factor', 'concentrates on patient resource use', 'Endpoints', 'Primary', 'Annualized Bleeding Rate (ABR) in the efficacy period', 'Secondary', 'ABR in the treatment period', 'Annualized spontaneous bleeding rate in the efficacy period', 'Annualized joint bleeding rate in the efficacy period', 'Change in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) physical', 'health score and total score in the treatment period', 'ABR in the onset period', 'Exploratory', 'Change in the following in the treatment period:', '- Treatment Satisfaction Questionnaire for Medication (TSQM) domain scores', '- Hemophilia Activities List (HAL) score', '-', 'Pediatric HAL (pedHAL) score', '-', 'EuroQol-5 dimension (EQ-5D) score', '-', 'Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL)', 'score', '-', 'Hemophilia Joint Health Score (HJHS)', 'Number of target joint bleeding episodes', 'Incidence and titer of antidrug antibodies to fitusiran in the fitusiran treatment arm', 'Antithrombin (AT) activity level over time', 'Thrombin generation over time', 'Fitusiran plasma levels', 'Annualized weight-adjusted use of factor concentrates', 'Change in patient resource use (eg, work/school attendance, visits to doctor/hospital)', 'Property of the Sanofi Group - strictly confidential', '7', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Safety', 'Incidence, severity, seriousness, and relatedness of adverse events (AEs)', 'Study Design', 'The ATLAS-A/B trial (ALN-AT3SC-004 [Sanofi Genzyme EFC14769]) is a multicenter,', 'multinational, randomized, open-label Phase 3 study designed to evaluate the efficacy and safety of', 'fitusiran in male patients aged >12 years, with hemophilia A or B without inhibitory antibodies to', 'factor VIII (FVIII) or factor IX (FIX), who are not receiving prophylactic therapy.', 'Eligible patients will be randomized in a 2:1 ratio to:', 'Fitusiran treatment arm: Fitusiran 80 mg administered subcutaneously (SC) as', 'prophylaxis once monthly, with use of on-demand factor concentrates for treatment of', 'breakthrough bleeding episodes', 'On-demand arm: On-demand factor concentrates for treatment of breakthrough bleeding', 'episodes', 'On-demand use of factor concentrates is defined as the use of these agents, as needed, for episodic', 'bleeding, and not on a regular regimen intended to prevent spontaneous bleeding. Throughout the', 'study, patients in the fitusiran treatment arm may receive on-demand treatment for breakthrough', 'bleeding episodes with factor concentrates, as appropriate.', 'Bleeding events and doses of factor concentrates administered during the conduct of the study will be', 'recorded in an electronic Diary (eDiary). Safety, quality of life, pharmacodynamic, and', 'pharmacokinetic data will also be collected.', 'All patients will be treated for a total of 9 months; patients randomized to the fitusiran treatment arm', 'will receive a total of 9 SC injections of fitusiran. Because the full PD effect of fitusiran is not', 'achieved until approximately 28 days after receiving the first dose, efficacy will be assessed during the', 'remaining 8 months on study (Day 29 to Month 9).', 'An independent data monitoring committee (DMC) will oversee the safety and overall conduct of this', 'study. The DMC will perform periodic reviews of data during the course of the clinical trial, and on an', 'ad hoc basis for review of emergent safety data, as defined in the DMC Charter for this clinical trial.', 'Patients from both the fitusiran and on-demand treatment arms who complete the study may be eligible', 'for participation in an open-label extension study. Following final fitusiran dose, for patients in the', 'fitusiran treatment arm patients who do not enroll in the extension study, AT activity level will be', 'monitored at monthly intervals until returning to an activity level of approximately 60% (per the central', 'laboratory) or per Investigator discretion in consultation with the study Medical Monitor.', 'Number of Planned Patients', 'Approximately 120 patients will be randomized, including approximately 26 patients with', 'hemophilia B and approximately 10 adolescents (12 to <18 years of age).', 'Property of the Sanofi Group - strictly confidential', '8', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}